Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Valentina Cesaroni, Fabio Blandini & Silvia Cerri. (2022) Dyskinesia and Parkinson’s disease: animal model, drug targets, and agents in preclinical testing. Expert Opinion on Therapeutic Targets 26:10, pages 837-851.
Read now
Read now
Sheilla Da Silva Barroso, Lorenna Emília Sena Lopes, Klebson Silva Santos & Margarete Zanardo Gomes. (2019) Technological prospection: patents mapping involving compounds for the treatment of L-DOPA-induced dyskinesias. Expert Opinion on Therapeutic Patents 29:12, pages 979-985.
Read now
Read now
Nataša Dragašević-Mišković, Igor Petrović, Iva Stanković & Vladimir S. Kostić. (2019) Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients. Expert Opinion on Pharmacotherapy 20:2, pages 219-230.
Read now
Read now
Silvia Cerri, Francesca Siani & Fabio Blandini. (2017) Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias. Expert Opinion on Investigational Drugs 26:7, pages 777-791.
Read now
Read now
Livia Dézsi & László Vécsei. (2014)
Safinamide for the treatment of Parkinson's disease. Expert Opinion on Investigational Drugs 23:5, pages 729-742.
Read now
Read now
Articles from other publishers (8)
Jayaram SARAVANAN & Praveen Thaggikuppe KRİSHNAMURTHY. (2022) Neuroprotective Effect of farnesol against Rotenone Induced Parkinson’s Disease in Drosophila melanogasterNeuroprotective Effect of farnesol against Rotenone Induced Parkinson’s Disease in Drosophila melanogaster. Hacettepe University Journal of the Faculty of Pharmacy.
Crossref
Crossref
Jie Wang, Wei-Wei Hu, Zhi Jiang & Mei-Jiang Feng. (2020) Advances in treatment of neurodegenerative diseases: Perspectives for combination of stem cells with neurotrophic factors. World Journal of Stem Cells 12:5, pages 323-338.
Crossref
Crossref
Changliang Liu. (2020) Targeting the cholinergic system in Parkinson’s disease. Acta Pharmacologica Sinica 41:4, pages 453-463.
Crossref
Crossref
Wen-Wen Wang, Xing-Ru Zhang, Jing-Ya Lin, Zeng-Rui Zhang, Zhen Wang, Si-Yan Chen & Cheng-Long Xie. (2019) Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa–Induced Dyskinesia via Lower β-Arrestin2 in 6-Hydroxydopamine Parkinson’s Rats. Frontiers in Pharmacology 10.
Crossref
Crossref
Faezeh Mokarian, Hamidreza Famitafreshi & Mahsa Hadipour Jahromy. (2018)
Berberis vulgaris
alleviates Levodopa-induced dyskinesia in male mice
. Herba Polonica 64:4, pages 44-49.
Crossref
Crossref
Veronica A. Antipova, Carsten Holzmann, Oliver Schmitt, Andreas Wree & Alexander Hawlitschka. (2017) Botulinum Neurotoxin A Injected Ipsilaterally or Contralaterally into the Striatum in the Rat 6-OHDA Model of Unilateral Parkinson’s Disease Differently Affects Behavior. Frontiers in Behavioral Neuroscience 11.
Crossref
Crossref
Svetlana A. Ivanova & Anton J. M. Loonen. (2016) Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding. Parkinson's Disease 2016, pages 1-5.
Crossref
Crossref
Etheresia Pretorius, Albe C Swanepoel, Antoinette V Buys, Natasha Vermeulen, Wiebren Duim & Douglas B Kell. (2014) Eryptosis as a marker of Parkinson's disease. Aging 6:10, pages 788-819.
Crossref
Crossref